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A B S T R A C T
Precision medicine can be defined as the prevention, investigation and treatment of diseases taking
individual variability into account. There are multiple ways in which the field of precision medicine may
be advanced; however, recent innovations in the fields of electronics and microfabrication techniques
have led to an increased interest in the use of implantable biosensors in precision medicine. Implantable
biosensors are an important class of biosensors because of their ability to provide continuous data on the
levels of a target analyte; this enables trends and changes in analyte levels over time to be monitored
without any need for intervention from either the patient or clinician. As such, implantable biosensors
have great potential in the diagnosis, monitoring, management and treatment of a variety of disease
conditions. In this review, we describe precision medicine and the role implantable biosensors may have
in this field, along with challenges in their clinical implementation due to the host immune responses
they elicit within the body.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
The Veterinary Journal
journal homepage: www.else vie r .com/ locate / t vj lIntroduction
Precision and personalised medicine are interchangeable terms,
with similar concepts. Due to concerns among clinicians and
scientists that the term “personalised” could be misunderstood,
leading patients to believe that unique treatments/drugs were
being developed specifically for each individual, the term
personalised medicine has now predominately been replaced
with precision medicine (Biesecker et al., 2011; Katsnelson, 2013).
Precision medicine is defined as the prevention, investigation and
treatment of diseases taking individual variability into account.
These factors include disease biomarkers, molecular signatures,
phenotype, environment and lifestyle (Ghasemi et al., 2016). This
approach allows individual patients to be classified into sub-
populations that differ in their susceptibility to a particular
disease, prognosis and response to treatment (Bu et al., 2016).
Precision medicine can therefore help to identify patients most* Corresponding author at: The Royal (Dick) School of Veterinary Studies and
Roslin Institute, University of Edinburgh, Easter Bush, Roslin, Midlothian, Edinburgh
EH25 9RG, UK.
E-mail address: s9900757@sms.ed.ac.uk (M. Gray).
https://doi.org/10.1016/j.tvjl.2018.07.011
1090-0233/© 2018 The Authors. Published by Elsevier Ltd. This is an open access articlikely to benefit from a specific treatment, thus improving clinical
outcomes whilst reducing side effects (Penet et al., 2014).
Even though precision medicine is not a new concept, it has
gained increased awareness and momentum in recent years, aided
by world leaders such as the former President of the United States
Barack Obama, who announced the “Precision Medicine Initiative”
at the beginning of 2015. This initiative aimed “to bring us closer to
curing diseases like cancer and diabetes – and to give us all access
to the personalised information we need to keep ourselves and our
families healthier” (Collins and Varmus 2015).
Although the role of precision medicine in everyday treatment
is currently limited, dedicated centres, such as The Centre for
Personalised Medicine in the UK and The Personalised Medicine
Coalition in the USA, should make the integration of precision
medicine into everyday healthcare practices more widespread in
the coming years (Carrasco-Ramiro et al., 2017). However, cross
disciplinary approaches involving engineering and chemistry may
be needed to make significant progress. While the application of
precision medicine is currently more focused on humans, its
concepts are equally applicable in the treatment of veterinary
patients.le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The physiology of disease tissue can be markedly different to
that of healthy tissue, with diseases such as cancer or diabetes
mellitus leading to measurable changes within the body.
Methodology that could provide continuous data on the levels
of a target analyte, enabling trends and changes in concentrations
over time to be analysed, without any need for intervention from
the patient or clinician, would be very valuable (Vaddiraju et al.,
2010). As such, implantable medical devices have great potential in
the diagnosis, monitoring, management and treatment of a variety
of disease conditions (Cavallini et al., 2015) (Fig. 1).
Advances in the fields of electronics and microfabrication
techniques have caused increased interest in the use of implant-
able medical devices in precision medicine. Biosensors are
analytical devices containing a biological sensing element that
transforms a biological response into electrical signals (Turner,
2013; Mehrotra, 2016). Biosensors have many different applica-
tions, from environmental monitoring and food safety, to security
and defence; however, the use of biosensors for medical
diagnostics represents the largest driver for biosensor develop-
ment and application today (Turner, 2013).
Implantable electrochemical biosensors
Biosensors are composed of two main parts; a bio-recognition
element and a transducer. The bio-recognition element of the
sensor identifies a target analyte, while a transducer converts the
output from the molecular recognition into an electrical signal
(Thévenot et al., 2001). Different molecular recognition elementsFig.1. Diagram showing the criteria that an ideal implantable biosensor should possess. T
operate within the therapeutic range of the target substance whilst in the presence of 
(negative immune reactions may cause the device to become non-functional), self-suffici
(the signal output transmitted to an external communication device should be in a mecan be employed, including enzymes, nucleic acids, antibodies,
proteins and peptides. Electrochemical biosensors have electrodes
as their transduction element (Thévenot et al., 2001).
Clark is credited with developing the first biosensor in 1962;
this ‘enzyme electrode’ (Clark and Lyons, 1962) was a concept built
on his earlier invention the Clark oxygen electrode (Clark, 1959).
Having enzymes as the molecular recognition element depends on
the catalytic conversion of an enzymatic substrate to a product.
Because enzymes have highly specific binding pockets, enzyme
electrodes have high selectivity against their chosen analyte (Zhu
et al., 2015). Clark’s paper described the electrochemical detection
of O2 or CO2 by immobilised enzymes. In one example, the enzyme
glucose oxidase (GOx) was entrapped on a platinum O2 electrode
over a semi-permeable dialysis membrane, with the amount of O2
consumed by the electrode acting as an indirect measure of glucose
levels (Clark and Lyons, 1962).
Electrochemical biosensors have the potential to offer the
sensitive and rapid detection of a wide range of biomarkers; their
relative fabrication simplicity, amenability to miniaturisation,
along with the reduced cost of instrumentation, has also furthered
interest in their development (Kokkinos et al., 2016).
Biosensors and metabolic diseases
One of the first major successful applications of implantable
biosensors was in the field of metabolic diseases, specifically
diabetes mellitus. Despite advances in insulin therapy delivery and
the development of more physiological insulin preparations
(Home, 2012), the avoidance of hypoglycaemic episodes still
remains a challenge (Cryer, 2015). Blood glucose measurementshese requirements include: sensitivity and specificity (the biosensor must be able to
complex solutions e.g. interstitial fluid or blood), biostability and biocompatibility
ency (in terms of power supply and control from external devices) and transmission
aningful form for ease of use for the patient/clinician).
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and amperometric home-use glucose sensors. Regular blood
sampling can be painful and time consuming, causing psychologi-
cal distress and poor patient compliance (Rubin and Peyrot, 2001);
non-compliance among diabetic patients has been estimated in
the range of 50–80% (Chatterjee, 2006). Similar issues are
encountered in veterinary patients. Commonly used monitoring
methods to manage diabetic dogs and cats are classified as direct or
indirect. Indirect monitoring includes the assessment of water
intake, quantification of glycosuria and ketonuria, and measure-
ment of glycosylated protein concentrations, whereas direct
monitoring includes serial or continuous blood glucose measure-
ments (Cook, 2012). Although serial blood glucose measurements
are the mainstay monitoring method used in clinical practice, this
can be problematic due to large day-to-day variations in blood
glucose levels in dogs (Fleeman and Rand, 2003) and stress
hyperglycaemia in cats (Rand et al., 2002). Owners predominately
rely on home-use urine tests to monitor glucose levels; however,
these urine tests only reflect the glucose levels over a large time
frame, and transient hypoglycaemia may be masked by hyper-
glycaemic periods. Even animals whose diabetes is under control
and experience several hours of euglycaemia will likely be
glycosuric for several hours a day (Cook, 2012). The Somogyi
effect is also seen in both dogs and cats, whereby sustained
rebound hyperglycaemia occurs after an acute decrease in blood
glucose levels; insulin levels therefore should not be increased
based on persistent hyperglycaemia. To overcome some of the
issues outlined with blood glucose measurements in dogs and cats,
glycosylated proteins such as glycosylated haemoglobin and
fructosamine concentrations can be measured to give a quantita-
tive indirect assessment of diabetes diagnosis and management
(Thoresen and Bredal, 1996; Loste and Marca, 2001; Cook, 2012).
The development of continuous glucose monitoring (CGM) over
the last 15 years aims to provide real-time interstitial glucose
readings, alerting patients to impending hypo- and hyperglycae-
mic episodes. Although CGM systems for veterinary patients are
not in mainstream use, they have been successfully used in clinics
(Davison et al., 2003; Wiedmeyer et al., 2003; Wiedmeyer and
DeClue, 2008). CGM systems can be connected with subcutaneous
insulin infusion systems, creating sensor augmented pumps with
the automated administration of insulin, acting as an artificial
pancreas (Cengiz et al., 2011; Kropff and Devries, 2016; Bally et al.,
2017).
Continuous glucose-monitoring systems using long-term (> 90
days) fully implantable sensors have now been brought to the
market (Eversense, Senseonics Inc.) (Dehennis et al., 2015). This
system uses an implanted glucose sensor, a removable wearable
smart transmitter and a mobile app to display real-time glucose
measurements. Long-term implantable CGM systems are benefi-
cial to patients as the number of times the sensor needs to be
replaced is decreased, thus reducing warm-up procedures and the
risk of sensor damage from each implantation (Kropff and Devries,
2016).
These types of amperometric enzyme-based biosensors have
also been utilised in the field of experimental neuroscience.
Regulatory disturbances in brain energy metabolism (particularly
in respect to glucose, lactate and pyruvate levels) can have a
negative impact on cognitive learning and memory (Hertz and
Gibbs, 2009), and is thought to be involved in multiple neurological
diseases/disorders (Moretti et al., 2003; Cloix and Hevor, 2009;
Kapogiannis and Mattson, 2011). An amperometric enzyme-based
multiplex biosensor device (MBD) for the monitoring of brain
glucose, lactate and pyruvate, has been developed using glucose
oxidase, lactate oxidase and pyruvate oxidase respectively at the
electrode surface. This biosensor was implanted into the medial
prefrontal cortex of anaesthetised rats, where researchers showedthat the biosensor was able to continuously and simultaneously
monitor these three metabolism-related biomarkers in a specific
brain region with temporal and spatial accuracy (Cordeiro et al.,
2015).
Biotelemetry
Biotelemetry (the remote measurement of an activity, function
or condition) utilises implantable technology as a means of
obtaining data in an experimental setting in conscious, unre-
strained animals. Electromyogram (EMG), electroencephalogram
(EEG), electrocardiogram (ECG), heart rate, blood pressure, body
temperature, activity and circadian rhythm data can be collected
using biotelemetry techniques (Bertram and Lothman, 1991;
Kramer et al., 2001; Güler and Übeyli, 2002; Kramer and Kinter,
2003; Bastlund et al., 2004; Weiergräber et al., 2005; Bassett
et al., 2014; Lundt et al., 2016). It is thought that information
obtained from conscious, unrestrained animals is likely to be
more comparable to that seen in humans, in contrast to classically
derived data from anaesthetised or restrained animals (Kramer
and Kinter, 2003). Wireless radiotelemetry has been used in a
variety of laboratory animals, including mice as small as 20 g and
fish, with transmitters commonly implanted either intraperito-
neally, subcutaneously or between abdominal muscle layers
(Snelderwaard et al., 2006; Bassett et al., 2014; Lundt et al., 2016).
Biotelemetry has been shown to be of value in the characterisa-
tion of various animal models of human diseases, including
epilepsy, sleep disorders, neurodegenerative and neuropsychiat-
ric disorders (Güler and Übeyli, 2002; Bastlund et al., 2004;
Williams et al., 2006). This technique also has a role in the
investigation of the pharmacokinetic, pharmacodynamic and
toxicological properties of drugs, helping to determine their
safety margins and efficacy. For example, EEG recordings can be
used to assess a drugs effect on the central nervous system,
including the detection of seizure activity (Bassett et al., 2014),
whereas ECG, heart rate and blood pressure can be used to
investigate the effects of cardiac drugs (Anderson et al., 1999).
One study, using radiotelemetry combined with an automatic
blood sampler and urine analysis, demonstrated the feasibility of
recording multiple telemetric and non-telemetric physiological
parameters simultaneously (Kamendi et al., 2010).
Biosensors and drug delivery
Different types of biosensors featuring drug delivery systems
have been developed with the ability to deliver drugs in response
to biosensor readings. Micro-electromechanical systems (MEMS)-
based drug delivery devices are one example, with BioMEMS
defined as a class of MEMS which incorporate biological entities or
have a biological application (Menon et al., 2013). The use of
techniques created for the electronics industry has enabled the
production of the micro-reservoirs, micropumps, valves and
sensors (Staples et al., 2006; Ngoepe et al., 2013) needed to make
miniaturised devices. These devices have the ability to sense,
monitor, mix, pump and control the flow of small amounts of fluid
(Nisar et al., 2008), some of which are commercially available
(Ngoepe et al., 2013). Smart polymers, which have been produced
to go through structural alterations when subjected to changes to
external stimuli such as temperature or pH (Ngoepe et al., 2013)
can also be used as biosensors. They have the ability to deliver
drugs when needed. One such example is the attachment of both
glucose oxidase and insulin within a hydrogel that is responsive to
changes in pH, enabling this smart polymer to act both as a sensor
of glucose concentration and as a drug delivery vehicle for insulin
(Traitel et al., 2000). These types of biosensor-drug delivery
systems can reduce the risk of overdosing/underdosing a patient
Fig. 2. Diagram outlining the mechanisms of hypoxia development in solid
tumours. Hypoxia is defined as a state of reduced O2 availability. Most mammalian
tissues function in O2 concentrations ranging from 2 to 9%, with O2 concentrations
<2% defined as hypoxic. It is estimated that up to 60% of locally advanced solid
tumours have heterogeneously distributed hypoxic tissue areas. Perfusion-limited
hypoxia is brought about by structural and functional abnormalities of the tumour
microvessels, leading to disturbances in blood flow and causing acute/transient
hypoxia. Diffusion-limited hypoxia results from the viable aerobic tumour cells
around the blood vessels utilising the available O2, giving rise to chronic hypoxia in
areas beyond the diffusion distance of O2 (150–180 mm). Anaemic hypoxia is caused
by tumour-associated and/or therapy-induced anaemia, leading to a reduced blood
O2 transport capacity.
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point (Smolensky and Peppas, 2007).
Implantable drug delivery systems have also great potential for
use in diseases in which treatment regimens are difficult to
implement. Osteoporosis affects bone density leading to weak-
ened/fragile bones. One treatment option for this condition is the
daily injection of human parathyroid hormone fragment (1-34)
[hPTH(1-34)] as an anabolic therapy, stimulating osteoblastic bone
formation (Cosman, 2006). This therapy can last up to 2 years,
which makes patient compliance problematic (Papaioannou et al.,
2007). The first-in-human testing of a wirelessly controlled drug
delivery microchip was used in the treatment of osteoporosis
(Farra et al., 2012); the device consisted of silicon chips with
multiple individual reservoirs filled with concentrated hPTH(1-34)
solution. Pharmacokinetic evaluation showed that the microchip
produced similar results to multiple daily injections, with bone
marker evaluation indicating that bone formation increased even
though a fibrous capsule developed around the implanted device.
This study is an excellent example of where implantable devices
can be utilised to overcome difficult treatment regimens and poor
patient compliance.
Implantable technology and cancer monitoring/treatment
Tumour physiology differs markedly from normal tissue
physiology. Tumours are characterised by areas of O2 depletion
(hypoxia and anoxia), glucose and energy deprivation, extracellu-
lar acidosis, high lactate levels and interstitial hypertension. This
unique tumour microenvironment (TME) is largely determined by
an abnormal tumour vasculature and its heterogeneous microcir-
culation (Vaupel, 2004).
Biosensors and the clinical monitoring of cancer progression
The TME strongly influences a tumours response to radiother-
apy (RT) and chemotherapy; therefore, monitoring the TME for
certain biomarkers, pH, O2, cancer metabolites or chemothera-
peutic drug concentrations could allow observation of the
treatment response, and improve the detection of recurrence or
metastasis. An implantable diagnostic device placed within the
tumour, or the surrounding tissue, following surgery or at the time
of biopsy would be one potential method to achieve this kind of
precision monitoring (Sedlaczek et al., 2002; Daniel et al., 2009).
This would be especially useful in areas where imaging (e.g. MRI/
CT) makes it difficult to distinguish between the tumour
recurrence, fibrosis, necrosis or benign lesions from previous
surgery and/or chemoradiotherapy treatment (e.g. gliomas)
(Verma et al., 2013). The first in vivo description of such a device
was used to detect soluble cancer biomarkers (the β subunit of
human chorionic gonadotrophin) in mice, using nanoparticle
magnetic relaxation switches (MRSw) enclosed within an im-
plantable device by a semipermeable membrane (Daniel et al.,
2009).
Tumour microenvironment and hypoxia
Tissue oxygenation is an important component of many cancers
(Vaupel, 2004; Bertout et al., 2008). The mechanisms involved in
the development of hypoxia in solid tumours include perfusion-
limited, diffusion-limited and anaemic hypoxia (Secomb et al.,
2012; Vaupel and Mayer, 2014) (Fig. 2). Hypoxia was one of the first
recognised modifiers of treatment outcomes, with a multitude of
studies published from 1909 onwards suggesting that O2 levels had
an influence on the radiosensitivity of cells (Bertout et al., 2008).
Papers published in the early 1950s confirmed this (Gray et al.,
1953). At a given dose of radiation, cancer cells in low O2 conditionscan tolerate a dose 2–3 times higher than aerobic cells. This O2
enhancement effect was highlighted in a large international study
which demonstrated that the pre-treatment tumour O2 status for
patients with head and neck cancer was a prognostic factor for
survival after RT (+/ surgery, chemotherapy, or radiosensitizer)
(Nordsmark et al., 2005).
Tumour functional imaging and implantable technology
To target hypoxic tumour areas, clinicians need to be able to
detect them. There are several approaches used for detection
which can be divided into indirect and direct methods. Molecular
reporters of O2, which form adducts with intracellular macro-
molecules at low O2 levels, can be detected through immunohis-
tochemistry and represent an indirect method of hypoxic
detection, as does the assessment of genes and proteins whose
levels are regulated by O2 levels (such as HIF-1 and CAIX) (Le and
Courter, 2008; Meehan et al., 2017). However, indirect methods
only allow the analysis of small portions of a tumour at any one
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is not represented. Also, the extent of hypoxia, and its changing
distribution throughout the tumour at the time of treatment, are
not given by these methods. Direct measurements of O2 can be
made using polarographic electrodes, such as the Eppendorf O2
electrode (Vaupel et al., 1991), but because of their invasive nature
these are not used clinically. Non-invasive imaging of tumour
hypoxia, through PET and MRI, allows clinicians to analyse tumour
hypoxia across the whole tumour volume (Hammond et al., 2014).
However, the images produced are static measurements that only
provide a snapshot of hypoxia at the time of analysis.
Therefore, despite advances, approaches that give an accurate
3D map of hypoxic areas within the entire tumour volume are not
available. As a result, there is an unmet clinical need for an
implantable biosensor that gives readings of the hypoxic areas/
levels in a tumour at the time of treatment, along with the spatial
and temporal changes that can occur. The Implantable Micro-
systems for Personalised Anti-Cancer Therapy (IMPACT) project
aims to produce such a device.1 The purpose of the project is to
manufacture implantable wireless sensors for the real-time
monitoring of tumour O2 levels, thus allowing RT to be delivered
at the most effective location and time (Marland et al., 2018).
Studies testing the manufactured sensors from the IMPACT project
are currently underway in animal models; should these produce
positive results, validation of the biosensors will be required in
clinical trials. If the IMPACT project is successful, it may lead to the
production of a biosensor that could prove to be a formidable tool
in realising biologically adapted RT.
Cancer treatment and implantable technology
Short-term implantable devices have been developed for high-
throughput drug sensitivity testing within solid tumours. A device
containing multiple reservoirs capable of releasing drugs into
spatially distinct tumour regions at concentrations that could be
achieved systemically has been described (Jonas et al., 2015).
Removal of tumour tissue surrounding the device 24 h after
implantation allowed assessment of each drugs anti-neoplastic
effect through immunohistochemical analysis (Jonas et al., 2015).
These types of devices could be employed to release drugs directly
within the TME, negating potential toxic systemic side effects,
while also aiding the identification of a patient's optimal drug
treatment before definitive systemic treatment commences.
Implantable technology could play an important role in the
treatment of brain tumours. The presence of the blood-brain
barrier is a significant limitation to the development of more
effective brain tumour therapies as it prevents the transfer of non-
lipid soluble molecules and particles larger than 500 Da in size into
the brain (Groothuis et al., 2000). Systemic toxicity for commonly
used chemotherapeutic agents is often reached before obtaining a
therapeutically effective concentration in the brain. MEMs-based
drug delivery systems have been used experimentally to deliver
drugs directly to the brain, thus overcoming the issues associated
with the blood brain barrier to achieve therapeutic doses of drugs
within primary brain tumours such as gliomas (Masi et al., 2012).
Radiotherapy plays a major role in the treatment of many
cancers. However, the clinical success of RT depends on the
accuracy of delivering the calculated dose to the desired area, with
tumour radiosensitivity also having an influence on treatment
response. Implantable dosimeters, such as the dose verification
system (DVS), can verify the radiation dose received by the target
volume for each treatment session/fraction (Beyer et al., 2008).1 See: Implantable Microsystems for Personalised Anti-Cancer Therapy. www.
impact.eng.ed.ac.uk (accessed 22 July 2018).This DVS has undergone clinical testing and received FDA approval
for use in breast and prostate cancer and could allow radiation
oncologists to optimise radiation treatment on an individual basis.
Biocompatibility and the foreign body response
For implantable sensors to be used clinically, they must be
characterised in terms of their biocompatibility; this should
incorporate both bio-functionality (does the sensor perform
correctly) and biosafety (the extent of local and systemic tissue
responses and the absence of carcinogenesis, mutagenesis and
cytotoxicity) (Arshady, 2003; Schoen and Anderson, 2004; Morais
et al., 2010). Unfortunately, following implantation biosensors
typically lose functionality over time; this detrimental effect is
largely due to biofouling (non-specific cell/protein absorption) that
occurs locally around the biosensor and results in a tissue reaction
known as the foreign body response (FBR) (Anderson, 2000;
Gretzer et al., 2006; Luttikhuizen et al., 2006; Anderson et al.,
2008) (Fig. 3).
Following implantation of any foreign substance, components
of both the acute as well as chronic inflammatory reactions may be
elicited (Anderson, 2001). Proteins associated with the acute
inflammatory response such as albumin, fibrinogen, complement,
and others can readily attach to biomaterial surfaces after
implantation (Jenny and Anderson, 2000; Keselowsky et al.,
2007; Anderson et al., 2008; McNally et al., 2008). The surface
characteristics of biomaterials can affect which of the inflamma-
tion-associated proteins bind to the surface of a biosensor, and
thereby represents a mechanism for potential modulation of the
ongoing inflammatory response to the device (Broughton et al.,
2006). Chronic inflammatory responses may also develop in
response to the biomaterial at the implantation site. Macrophages
are a key cell mediator of the chronic response to implanted
biomaterials, through their roles in foreign body giant cell
formation (FBGC), and the production of degradative enzymes
and inflammatory mediators such as reactive O2 species (Henson,
1971a; Henson, 1971b; Anderson, 2000; Broughton et al., 2006;
Castro et al., 2014); it is these reactions that can lead to biomaterial
degradation and device failure (Haas, 2007; Anderson et al., 2008).
Macrophages also elaborate numerous pro-fibrotic factors, which
lead to formation of a fibrous capsule surrounding the biosensor
(Song et al., 2000). The fibrous wall, combined with the FBGC,
creates a barrier surrounding the implant which can lead to
impaired function of the biosensor.
The majority of the literature related to the FBR focuses on
materials that are implanted into normal tissue. However, one
paper investigated the FBR using cotton thread implanted within
rodent tumours compared to that seen in normal tissues (Mahoney
and Leighton, 1962). They concluded that the response within the
tumour was minimal compared to that seen in the normal tissues.
Although more research is required on the effects of implanting
devices directly into tumours, the results published in this paper
indicated that the FBR may be decreased within tumours. This has
important implications for the future use of implantable devices in
cancer therapy.
Regulations governing implantable medical devices and
challenges in bringing implantable biosensors to the clinic
In 1992 the International Standards Agency (ISO) was set up as a
joint project between Canada, Great Britain and the USA. This
organisation developed and published international standards on
the Biological Evaluation of Medical Devices: ISO 10933, with
implantable biosensors being classified as devices in contact with
tissues for more than 30 days. The document describes methods
for biocompatability testing prior to clinical trials and includes
Fig. 3. Diagram outlining the stages of inflammation that occur following the implantation of a medical device/biosensor. These inflammatory phases include: tissue injury,
blood–biomaterial interactions with provisional matrix formation, acute and chronic inflammation and the formation of granulation tissue with fibrosis/fibrous capsule
development. Mast cells and PMNs are the predominant cell types present in the acute inflammatory phase, while macrophages drive the later inflammatory responses. The
provisional matrix, formed by biomaterial adherent proteins, contributes to ongoing inflammation through cytokine, chemoattractant and growth factor release. These
substances include: transforming growth factor beta, platelet-derived growth factor, CXCL4, leukotriene and interleukin-1. Within 2 days following implantation, PMN
numbers decrease as they undergo apoptosis and are engulfed by macrophages. Macrophages enhance the propagation of the chemoattractive signals through the production
of: platelet derived growth factor, tumour necrosis factor, IL-6, granulocyte-colony stimulating factor, chemokine (C-C motif) ligand 2 and granulocyte macrophage colony
stimulating factor. The cytokines IL-4 and IL-13 are important factors in FBGC formation, enhancing monocyte adhesion, macrophage differentiation and fusion. The end
result of the FBR is the production of granulation tissue with subsequent fibrous capsule formation. This reaction causes a ‘walling-off’ of the biosensor from its immediate
surrounding area; this, combined with the degradative chemicals released from the FBGC, can lead to a loss of biosensor function.
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ity, reproductive and developmental toxicity, biofunctionality
(adhesion, spreading, biosynthetic function), hemocompatibility
and degradation assessment. In vivo assessment includes tests for
local tissue effects after implantation, ethylene oxide residues,
degradation of materials, irritation and sensitisation, along with
systemic toxicity (ISO, 1992). The Food and Drug Administration
has also been involved in the production of regulations specifically
for the use of implantable biomaterials with drug release systems.
Although these in vitro tests are excellent for initial screening
processes, animal models are required to evaluate tissue reactions.
Various methods of in vivo biocompatability testing have been
developed, such as the cage implant system (Koschwanez and
Reichert, 2007), a chamber system (Papenfuss et al., 1979; Ertefai
and Gough, 1989) and an avian chorioallantoic membrane (CAM)
system of a developing chick embryo (Valdes et al., 2002; Valdes
et al., 2003). These methods allow harvesting of tissue or fluid in
the region of the implanted biomaterial, which can be analysed to
assess the collagen capsule, inflammatory response and presence
of capillaries.
Implantable medical devices must conform to regulatory bodies
to ensure patient safety, with implantable biosensors coming
under The Active Implantable Medical Devices Directive 90/385/
ECC, developed by the Medicines and Healthcare products
regulatory Agency. EU regulatory frameworks are undergoing
revision after shortcomings identified within the system, which
were highlighted by cases such as metal-on-metal hip implants
and Poly Implant Prosthese (PIP) breast implants. Manufacturers ofimplantable medical devices must provide evidence of product
safety and performance. However, clinical evidence is not always
required; using ‘equivalence data’/published clinical work of
similar devices can decrease the time in getting a product to
market, but could potentially lead to safety concerns as each device
is not fully evaluated. Once implants have gained market approval,
post-market surveillance is required to pick up limitations/adverse
incidents by patients, clinicians and manufacturers.
Human factor studies, which focus on the interactions between
devices and people, are also applicable to veterinary patients.
However, the opinions of patients or pet owners themselves can
often be overlooked by researchers and clinicians, which has led to
difficulties in the development of new technologies. For example, a
lack of prior consultation with members of the deaf community
with respect to cochlear implants meant that the development and
use of this technology was met with patient resistance (Blume,
1999; Ramsden, 2013). Similar studies for implantable cardiac
defibrillators have shown that device implantation can lead to
significant psychological distress in patients (Duru et al., 2001; Ooi
et al., 2016).
Veterinary-orientated human factor studies should help ensure
that pet owners can use implanted devices (such as continuous
glucose monitoring systems) safely and effectively, making
informed treatment decisions based on sensor readings. The use
of social scientists in the development of implantable medical
devices is also important as they can be involved in the
investigation of patient groups/pet owners to see if they would
accept having devices implanted into their bodies/pets as part of
M. Gray et al. / The Veterinary Journal 239 (2018) 21–29 27the treatment regime, while also evaluating the ethical implica-
tions of using these technologies (Ikegwuonu et al., 2015). The
integration of these types of studies at the very beginning of any
future projects would aid in a greater understanding of the disease
process, and foster ways in which implantable sensor technology
can be best developed to enhance patient treatment.
Conclusions
Since the development of the first glucose electrochemical
sensor, technological advances in the fields of biocompatible
material development, wireless power supply, miniaturisation
techniques and bioengineering has led to a considerable amount of
research focusing on the development of implantable biosensors,
both with and without drug delivery systems. These devices could
contribute significantly to the field of precision medicine; devices
are being engineered to make continuous monitoring of patients
possible, reducing the number of invasive interventions required
and enabling drug treatments to be administered at specified
times. Overall, implantable biosensors have the potential to
improve the management of patient health and quality of life,
increasing survival rates while reducing health care costs. Detailed
genotypic and phenotypic analysis of individual patients is
becoming more readily available and is happening in parallel to
the development of new drugs and diagnostics. This will allow
precision veterinary medicine to become a reality, but these
advances still necessitate new technologies, such as implantable
biosensors, to assess patients in real time. The development of
implantable biosensors represents the intersection of engineering,
chemistry, social science, medicine and veterinary medicine and
underscores the importance of working across disciplines to
advance patient care; these developments could accelerate a step
change in the diagnosis and treatment of disease, supporting new
initiatives in livestock species to underpin precision agriculture.
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